A simple, sensitive, and specific method for furosemide (FUR) analysis by reverse-phase-HPLC was developed using a Spherisorb C18 ODS 2 column. A chromatographic analysis was carried out using a mobile phase consisting of acetonitrile and 10？mM potassium phosphate buffer solution: 70？:？30 (v/v) at pH 3.85, at a flow rate of 1？mL·min？1. The UV-detection method was carried out at 233？nm at room temperature. Validation parameters including limit of detection (LOD), limit of quantitation (LOQ), linearity range, precision, accuracy, robustness, and specificity were investigated. Results indicated that the calibration curve was linear ( ) in the range of 5.2 to 25,000？ng·mL？1, with ε value equal to ？L·M？1·cm？1. The LOD and LOQ were found to be 5.2 and 15.8？ng·mL？1, respectively. The developed method was found to be accurate (RSD less than 2%), precise, and specific with an intraday and interday RSD range of 1.233–1.509 and 1.615 to 1.963%. The stability of native FUR has also been performed in simulated perilymph and endolymph media (with respective potency in each medium of % and %, ) after 6 hours. This method may be routinely used for the quantitative analysis of FUR from nanocarriers, USP tablets and release media related to hearing research 1. Introduction Furosemide, 5-(aminosulfonyl)-4-chloro-2-[(2 furanylmethyl) amino] benzoic acid, (FUR) a loop diuretic has been used in the treatment of congestive heart failure and edema (Figure 1). FUR acts on thick ascending limb of the loop of Henle leading to a loss of sodium, potassium, and chloride that are dispatched in the urine [1]. This results in a decrease in sodium and chloride reabsorption, while increasing the excretion of potassium in the distal renal tubule. The diuretic effect of orally administered FUR appears within 30 minutes to 1 hour and is maximal in the first or second hour [2]. For the treatment of cardiac diseases, its daily dose is 20–80？mg for adults [3]. For pediatric use this dose is ranged from 1？mg·kg？1 up to a maximum of 40？mg daily neonates [3]. Figure 1: Chemical structure of furosemide. FUR has been reported to be the etiologic agent responsible for the permanent sensorineural hearing loss [4]. Recent work has demonstrated that FUR decreases the active cochlear mechanics in reducing the threshold shift following broadband continuous noise [5]. Thereby, it reduces the mobility of the basilar membrane of the cochlea and decreases the transduction that normally results from the bending of stereocilia on hair cells [6]. Therefore, FUR can be an appropriate drug model to target the
References
[1]
G. Giebisch, “The use of a diuretic agent as a probe to investigate site and mechanism of ion transport processes,” Arzneimittel-Forschung, vol. 35, no. 1, pp. 336–342, 1985.
[2]
S. A. Qureshi and I. J. McGilveray, “Assessment of pharmaceutical quality of furosemide tablets from multinational markets,” Drug Development and Industrial Pharmacy, vol. 24, no. 11, pp. 995–1005, 1998.
[3]
D. P. Patel, C. M. Setty, G. N. Mistry et al., “Development and evaluation of ethyl cellulose-based transdermal films of furosemide for improved in vitro skin permeation,” The American Association of Pharmaceutical Scientists PharmSciTech, vol. 10, no. 2, pp. 437–442, 2009.
[4]
C. A. Quick and W. Hoppe, “Permanent deafness associated with furosemide administration,” Annals of Otology, Rhinology and Laryngology, vol. 84, no. 1, pp. 94–101, 1975.
[5]
C. Adelman, J. M. Weinberger, L. Kriksunov, and H. Sohmer, “Effects of furosemide on the hearing loss induced by impulse noise,” Journal of Occupational Medicine and Toxicology, vol. 6, no. 1, article 14, 2011.
[6]
M. A. Ruggero and N. C. Rich, “Furosemide alters organ of Corti mechanics: evidence for feedback of outer hair cells upon the basilar membrane,” Journal of Neuroscience, vol. 11, no. 4, pp. 1057–1067, 1991.
[7]
J. G. Yorgason, J. N. Fayad, and F. Kalinec, “Understanding drug ototoxicity: molecular insights for prevention and clinical management,” Expert Opinion on Drug Safety, vol. 5, no. 3, pp. 383–399, 2006.
[8]
W. F. Sewell, “The effects of furosemide on the endocochlear potential and auditory-nerve fiber tuning curves in cats,” Hearing Research, vol. 14, no. 3, pp. 305–314, 1984.
[9]
K. Do, K. Baker, M. Praetorius, and H. Staecker, “A mouse model of implantation trauma,” International Congress Series, vol. 1273, pp. 167–170, 2004.
[10]
Y. Shinomori, D. S. Spack, D. D. Jones, and R. S. Kimura, “Volumetric and dimensional analysis of the guinea pig inner ear,” Annals of Otology, Rhinology and Laryngology, vol. 110, no. 1, pp. 91–98, 2001.
[11]
E. E. L. Swan, M. J. Mescher, W. F. Sewell, S. L. Tao, and J. T. Borenstein, “Inner ear drug delivery for auditory applications,” Advanced Drug Delivery Reviews, vol. 60, no. 15, pp. 1583–1599, 2008.
[12]
M. Thorne, A. N. Salt, J. E. DeMott, M. M. Henson, O. W. Henson Jr., and S. L. Gewalt, “Cochlear fluid space dimensions for six species derived from reconstructions of three-dimensional magnetic resonance images,” Laryngoscope, vol. 109, no. 10, pp. 1661–1668, 1999.
[13]
M. E. Bosch, A. J. R. Sánchez, F. S. Rojas, and C. B. Ojeda, “Recent developments in analytical determination of furosemide,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 3, pp. 519–532, 2008.
[14]
P. Campíns-Falcó, R. Herráez-Hernández, and A. Sevillano-Cabeza, “Improved detection limits for screening of diuretics by coupled liquid chromatography and ultraviolet-visible spectrophotometry,” Journal of Chromatography B, vol. 612, no. 2, pp. 245–251, 1993.
[15]
I. Nakurte, A. Keisa, and N. Rostoks, “Development and validation of a reversed-phase liquid chromatography method for the simultaneous determination of indole-3-acetic acid, indole-3-pyruvic acid, and abscisic acid in barley (Hordeum vulgare L.),” Journal of Analytical Methods in Chemistry, vol. 2012, Article ID 103575, 6 pages, 2012.
[16]
S. Carda-Broch, J. Esteve-Romero, and M. C. García-Alvarez-Coque, “Furosemide assay in pharmaceuticals by micellar liquid chromatography: study of the stability of the drug,” Journal of Pharmaceutical and Biomedical Analysis, vol. 23, no. 5, pp. 803–817, 2000.
[17]
A. A. Nava-Ocampo, E. Y. Velázquez-Armenta, H. Reyes-Pérez, E. Ramirez-Lopez, and H. Ponce-Monter, “Simplified method to quantify furosemide in urine by high-performance liquid chromatography and ultraviolet detection,” Journal of Chromatography B, vol. 730, no. 1, pp. 49–54, 1999.
[18]
Y. S. El-Saharty, “Simultaneous high-performance liquid chromatographic assay of furosemide and propranolol HCL and its application in a pharmacokinetic study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 4, pp. 699–709, 2003.
[19]
H. J. Guchelaar, L. Chandi, O. Schouten, and W. A. van den Brand, “A high performance liquid chromatographic method for the screening of 17 diuretics in human urine,” Fresenius' Journal of Analytical Chemistry, vol. 363, no. 7, pp. 700–705, 1999.
[20]
V. R. Ram, P. N. Dave, and H. S. Joshi, “Development and validation of a stability-indicating HPLC assay method for simultaneous determination of spironolactone and furosemide in tablet formulation,” Journal of Chromatographic Science, vol. 50, no. 8, pp. 721–726, 2012.
[21]
D. Q. Chen, J. M. An, Y. L. Feng, T. Tian, X. Y. Qin, and Y. Y. Zhao, “Cloud-point extraction combined with liquid chromatography for the determination of ergosterol, a natural product with diuretic activity, in rat plasma, urine, and faece,” Journal of Analytical Methods in Chemistry, vol. 2013, Article ID 479056, 8 pages, 2013.
[22]
ICH, “Validation of analytical procedures: methodology, adopted in 1996,” in Proceedings of the International Conference On Harmonisation, Geneva, Switzerland, 2005.
[23]
P. Wangemann and J. Schacht, “Homeostatic mechanisms in the cochlea,” in The Cochlea, P. A. Dallos and R. R. Fay, Eds., pp. 130–185, Springer, New York, NY, USA, 1996.
[24]
I. Youm, J. B. Murowchick, and B. B. C. Youan, “Entrapment and release kinetics of furosemide from pegylated nanocarriers,” Colloids and Surfaces B, vol. 94, pp. 133–142, 2012.
[25]
M. Pelillo, M. E. Cuvelier, B. Biguzzi, T. G. Toschi, C. Berset, and G. Lercker, “Calculation of the molar absorptivity of polyphenols by using liquid chromatography with diode array detection: the case of carnosic acid,” Journal of Chromatography A, vol. 1023, no. 2, pp. 225–229, 2004.
[26]
M. Efentakis, A. Koutlis, and M. Vlachou, “Development and evaluation of oral multiple-unit and single-unit hydrophilic controlled-release systems,” The American Association of Pharmaceutical Scientists PharmSciTech, vol. 1, no. 4, pp. 62–70, 2000.
[27]
B. Devarakonda, D. P. Otto, A. Judefeind, R. A. Hill, and M. M. de Villiers, “Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes,” International Journal of Pharmaceutics, vol. 345, no. 1-2, pp. 142–153, 2007.
[28]
L. J. Henderson, “Concerning the relationship between the strength of acids and their capacity to preserve neutrality,” The American Journal of Physiology, vol. 21, no. 4, pp. 173–179, 1908.
[29]
K. A. Hasselbalch, “Die Berechnung der Wasserstoffzahl des Blutes aus der freien und gebundenen Kohlens？ure desselben, und die Sauerstoffbindung des Blutes als Funktion der Wasserstoffzahl,” Biochemische Zeitschrift, vol. 78, pp. 112–144, 1917.
[30]
A. Guzmán, L. Agüí, M. Pedrero, P. Yá？ez-Sede？o, and J. M. Pingarrón, “Flow injection and HPLC determination of furosemide using pulsed amperometric detection at microelectrodes,” Journal of Pharmaceutical and Biomedical Analysis, vol. 33, no. 5, pp. 923–933, 2003.
[31]
N. Sultana, S. Shamim, M. A. S. Gul, and M. S. Arayne, “Simultaneous determination of gemifloxacin and diuretics in bulk, pharmaceutical dosage forms and human serum by RP-HPLC,” Quimica Nova, vol. 33, no. 7, pp. 1590–1593, 2010.
[32]
N. épshtein, “Structure of chemical compounds, methods of analysis and process control validation of HPLC techniques for pharmaceutical analysis,” Pharmaceutical Chemistry Journal, vol. 38, no. 4, pp. 40–56, 2004.
[33]
“Validation od analytical procedures: text and methodology,” in International Conference on Harmonization, of Thechnical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q2 (R1), Geneva, Switzerland, 2005.
[34]
T. Galaon, S. Udrescu, I. Sora, V. David, and A. Medvedovici, “High-throughput liquid-chromatography method with fluorescence detection for reciprocal determination of furosemide or norfloxacin in human plasma,” Biomedical Chromatography, vol. 21, no. 1, pp. 40–47, 2007.
[35]
C. D. Mills, C. Whitworth, L. P. Rybak, and C. M. Henley, “Quantification of furosemide from serum and tissues using high-performance liquid chromatography,” Journal of Chromatography B, vol. 701, no. 1, pp. 65–70, 1997.
[36]
S. Chawla, S. Ghosh, V. Sihorkar, R. Nellore, T. R. S. Kumar, and N. R. Srinivas, “High-perfomance liqiud chromatography method development and validation for simultaneous determination of five model compounds, antipyrine metoprolol, ketoprofen, furosemide and phenol red, as a tool for standardization of rat in situ intestinal permeability studies using timed wavelength detection,” Biomedical Chromatography, vol. 20, no. 4, pp. 349–357, 2006.
[37]
J. J. Pesek and M. T. Matyska, “How to retain polar and nonpolar compounds on the same HPLC stationary phase with an isocratic mobile phase,” LC-GC North America, vol. 2, no. 9, pp. 1–4, 2006.
[38]
S. Bankey, G. Tapadiya, J. Lamale, D. Jain, S. Saboo, and S. S. Khadabadi, “RP-HPLC method development and its validation for quantitative determination of rimonabant in human plasma,” Journal of Analytical Methods in Chemistry, vol. 2012, Article ID 625979, 4 pages, 2012.
[39]
D. Zendelovska and T. Stafilov, “Sample preparation and RPHPLC determination of diuretics in human body fluids,” Acta Pharmaceutica, vol. 56, no. 2, pp. 115–142, 2006.
